STERIS plc (NYSE: STE) (“STERIS” or the “Company”) today announced that it has completed the previously announced acquisition of Cantel Medical, a global provider of infection prevention products and services to endoscopy, dental, dialysis and life sciences Customers.
“We are pleased to announce the closing of the Cantel Medical acquisition, which will complement and extend STERIS’s product and service offerings, global reach, and Customers,” said Walt Rosebrough, President and Chief Executive Officer of STERIS. “We welcome Cantel people to the STERIS team, and look forward to working together to create more value for our customers, our people, and our shareholders.”
Guggenheim Securities served as financial advisor to STERIS and Jones Day as legal counsel. JPMorgan Chase Bank, N.A., served as sole lead arranger and bookrunner in respect of certain financing. Centerview Partners LLC served as exclusive financial advisor to Cantel and Wachtell, Lipton, Rosen & Katz as legal counsel.
Source: Biospace
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
